Events

ADR Partnership Awareness Day
DEC
Tue
17
10:00 - 12:00

This was 1 year ago

Location

Online

Programmes
Digital, Industry & Space AI Continent

An online event designed to drive dialogue and collaboration on critical topics shaping the future of AI, Data, and Robotics in Europe. This year, ADR will explore the convergence of AI and Data regulation, Interoperability and Trustworthy AI, Generative AI, and foundational models, with a special focus on their integration into robotics technologies.

Open to policymakers, researchers, innovators, industry leaders, and all stakeholders in the ADR ecosystem, the event features two engaging tracks: one on building an ecosystem of trust and accountability and the other on fostering European excellence and best practices. Whether you're navigating regulatory landscapes or exploring cutting-edge innovation, ADR Awareness Day 2024 is your platform to connect, contribute, and inspire progress.

More information & registration on the event website

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.